Au@Prussian Blue Hybrid Nanomaterial Synergy with a Chemotherapeutic Drug for Tumor Diagnosis and Chemodynamic Therapy

• DOI: 10.1021/acsami.9b13470
• Publication Date: 2019-10-02T09:04:46Z
• Authors: Lifeng Hang; Hailiang Li; Tao Zhang; Dandan Men; Cong Zhang; Peng Gao; Qianling Zhang
• Keywords: Prussian blue; Nanomaterials; Cancer Therapy; Chemotherapeutic drugs

Recently, the chemodynamic therapy (CDT) has been widely reported and applied to tumor therapy. However, only low level hydroxyl radicals (•OH) generated by endogenous hydrogen peroxide alone are insufficient kill cancer cells. To overcome therapeutic effect, this study reports a novel CDT based on Fenton catalyst Au@Prussian blue nanocubes (Au@PB NCs), subsequently encapsulated with doxorubicin (Dox). The in vitro vivo results indicate that Dox-Au@PB NCs can take synergistic effects suppressor CDT. In addition, Au@PB possess high X-ray computed tomography contrast enhanced efficiency about ∼27.13 HU·mL·mg-1. This highlights great potential of for diagnosis